Expression and fine mapping of murine vasoactive intestinal peptide receptor 1

被引:0
作者
Bahri Karacay
M.Sue O’Dorisio
Kim Kasow
Clay Hollenback
Ralf Krahe
机构
[1] University of Iowa,Division of Hematology/Oncology, Department of Pediatrics
[2] Saint Jude Children’s Hospital,Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics and the Comprehensive Cancer Center
[3] The Ohio State University,undefined
来源
Journal of Molecular Neuroscience | 2001年 / 17卷
关键词
Mouse; VPAC; cDNA; mapping; expression;
D O I
暂无
中图分类号
学科分类号
摘要
Vasoactive intestinal peptide (VIP) plays multiple roles in the nervous, endocrine, and immune systems as a neurotransmitter, a hormone, and a cytokine. VIP is widely distributed in neurons of the central and peripheral nervous systems (CNS/PNS), and recently has been found to be an important neuroprotective agent. VIP actions are mediated through specific G protein-coupled receptors. We have cloned the cDNA of VIP receptor subtype 1 (VIPR1+ or VPAC1) and have demonstrated the quantitative expression profile in mice. Fluorometric real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis demonstrated that VPAC1 is expressed in all tissues examined. Expression was highest in the small intestine and colon followed by the liver and brain. The high level of VPAC1 expression in forebrain and cerebellum suggests that VPAC1 may mediate the neuroprotective effect of VIP. We have refined the chromosomal localization of the mouse, rat, and human VPAC1 genes. This fine mapping of the VPAC1 gene extends the respective regions of synteny between the distal region of mouse chromosome 9, rat chromosome 8q32, and human chromosome 3p21.33-p21.31. Thus, VPAC1 constitutes a functional-positional candidate for the tumor-suppressor function mapped to human 3p22-p21 where loss-of-heterozygosity is observed in small-cell lung carcinoma (SCLC) cell lines and primary tumors. Availability of the cDNA sequences for mouse VPAC1 will facilitate the generation of VPAC1 null mutant animals. Such studies will ultimately enhance our understanding of the role of VIP in the nervous system.
引用
收藏
页码:311 / 324
页数:13
相关论文
共 304 条
[1]  
Adamou J. E.(1995)Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor Biochem. Biophys. Res. Commun. 209 385-392
[2]  
Aiyar N.(1996)VIP, PACAP, and Related Peptides Second International Symposium Annals of the New York Academy of Sciences 805 1-748
[3]  
VanHorn S.(1971)Intestinal secretion: stimulation by peptides Science 174 422-424
[4]  
Elshourbagy N. A.(1983)Demonstration of a functional receptor for vasoactive intestinal polypeptide on Molt 4b T lymphoblasts Regul. Pept. 6 1-12
[5]  
Arimura A.(1996)The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation Adv. Neuroimmunol. 6 5-27
[6]  
Said S. I.(1997)Adrenal vasoactive intestinal peptide participates in neonatal corticosteroid production in the rat Am. J. Physiol. 273 R1163-R1172
[7]  
Barbezat G.(1986)Vasoactive intestinal peptide and electrical activity influence neuronal survival Proc. Natl. Acad. Sci. USA 83 1159-1162
[8]  
Grossman M.(1990)Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen J. Neurosi. Res. 25 386-394
[9]  
Beed E. A.(1991)Identification and immunohistochemistry of cholinergic and non-cholinergic circular muscle motor neurons in the guinea-pig small intestine Neuroscience 42 863-878
[10]  
O’Dorisio M. S.(1995)Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP Biochem. Biophys. Res. Commun. 206 246-252